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Introduction
Cardiac troponins are structural proteins in the contractile apparatus of the myocyte.
Upon myocardial damage, they are released into the circulation (1) and they are therefore central in the diagnosis of myocardial infarction (2) . Measurement of cardiac troponin with early assays was considered as a dichotomous test, classifying patients as being positive or negative for myocardial infarction. The advent of high-sensitivity cardiac troponin (hs-cTn) assays in recent years has changed this paradigm. Highsensitivity assays have allowed cardiac troponin to be considered as a quantitative measure of cardiac myocyte injury in the setting of myocardial infarction, and can measure cardiac troponin at low concentrations in individuals without myocardial infarction, where it can be regarded as a marker for myocardial stress (2, 3) .
We have previously demonstrated in a meta-analysis of 29 studies that cardiac troponin concentration in people without manifest cardiovascular disease (CVD) is associated with the long-term risk of developing coronary heart disease or stroke (4) . In addition to these two outcomes, hs-cTn may also be a prognostic marker for the development of heart failure (HF). Identification of better prognostic marker for incident HF is important because HF is associated with poor survival, reduced quality of life, and significant healthcare costs (5) . Furthermore, as reported by a recent UK-based study, HF has become the most common initial presentation of CVD (6) . Still, prediction models aiming to identify individuals at high risk of HF are currently not included in CVD prevention guidelines (7, 8) and are not established in clinical practice (9) . The potential of cardiac biomarkers in HF prediction is exemplified by a meta-analysis showing natriuretic peptides improve risk discrimination and classification in general population studies (10) . Risk scores for HF could help target preventive medication, such as statins (11) , intensive blood pressure control (12) , and angiotensin-converting-enzyme inhibitors (13) .
The aim of this study was to systematically collate and appraise the available evidence regarding the association between hs-cTn and incident HF and the added value of hs-cTn in HF prediction.
Methods
This systematic review is reported in accordance with the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guideline (14) and the protocol was registered prospectively with PROSPERO (CRD42017054828).
Literature search
Electronic searches of Pubmed, Embase and Web of Science were performed on 3rd January 2017 (search strategy detailed in Supplementary table 1) with no filters or language restrictions applied. This was supplemented by review of relevant conference proceedings (i.e. American Heart Association Scientific Sessions, American College of Cardiology Sessions, European Society of Cardiology Annual Congress from 2014-2016) and of reference lists of identified studies. The searches were conducted by two independent investigators (J.E. and S.D.) and any discrepancies were resolved, by consensus, with a third investigator (S.P.).
Study eligibility criteria
To be eligible for inclusion, studies were required to: (i) have a prospective study design, including studies nested in randomized controlled trials; (ii) have enrolled individuals without HF at baseline; (iii) had measured high-sensitivity cardiac troponin; and (iv) had recorded incident HF events over at least 1 year. Studies were excluded which involved patients in the early phase after acute myocardial infarction, undergoing cardiotoxic chemotherapy or with established myocardial or multisystem disease (e.g. sarcoidosis, amyloidosis).
Data extraction
Using a pre-specified data collection sheet, data were collated on population type (general vs high-risk populations), mean age, sex, ethnicity, baseline history of hypertension, diabetes, and CVD, hs-cTn assay type and manufacturer, number of participants, duration of follow-up and number of incident HF events. Furthermore, we assessed quality of included studies using the Newcastle-Ottawa tool for cohort studies (15) , which considers participant selection, exposure measurement, ascertainment of outcomes, covariate adjustment, and adequacy of follow up. We also recorded which methods studies used to record incident HF events and how they defined them (fatal, non-fatal, or both). Hazard ratios for the association between hs-cTn and incident HF were extracted with the following levels of covariate adjustment, where available: (1) unadjusted or adjusted only for age and sex, (2) adjusted for demographic factors, conventional CVD risk factors and/or biomarkers other than natriuretic peptides, (3) adjusted for demographic factors, conventional CVD risk factors, non-natriuretic peptide biomarkers and natriuretic peptide levels. Where reported, C-indices as a measure for risk discrimination were extracted for predictive models with and without hs-cTn assessment.
Statistical analysis
All statistical analyses were performed using Stata Version 13 (StataCorp, USA) and a 2-sided p-value of <0.05 was deemed to represent statistical significance in the primary analysis and <0.01 in meta-regression analyses due to multiple testing. Studies reported hazard ratios in different ways. These included a hazard ratio describing those above and below a specific threshold, between top and bottom quartiles or quintiles, per unit increase or per standard deviation increase in hs-cTn. In order to allow direct comparison of study specific hazard ratios, hazard ratios were transformed to represent the hazard ratio for the top third versus the bottom third of hs-cTn concentration within a given study. This transformation was performed under the assumption that the exposure variable is normally distributed and a log-linear association between exposure and outcome, as previously described (16, 17) . When estimates were presented both by groups of cardiac troponin as a categorical variable and as a continuous measure, the continuous measure was used as this is more compatible with the linear assumption used when transforming hazard ratios.
For the primary analysis, the most adjusted study-specific hazard ratios for the association between hs-cTn and incident HF were pooled by random effects inversevariance weighted meta-analysis using the method of DerSimonian and Laird (18) . This random-effects method was selected a priori due to a degree of anticipated heterogeneity in the populations studied and the design of included studies. Between-study heterogeneity was quantified using the I 2 statistic (19) .
Secondary analyses pooled sex-specific hazard ratios using data from studies that reported associations separately in both men and women and compared hazard ratios according to the three pre-specified levels of covariate adjustment. Furthermore, metaregression was used to test whether associations differed according to study-level characteristics. For categorical study-level characteristics, pooled hazard ratios were calculated within each subgroup. For continuous variables, study-specific estimates of the association between hs-cTn and HF were plotted against the value of the variable of interest and a regression line fitted. The presence of publication bias was assessed with funnel plots and Egger's test (20) .
Results

Summary of included studies
Electronic searches yielded 2,982 unique citations (Figure 1) . Shortly after the date of the electronic searches, full text manuscripts of two abstracts identified in the search process were published and included (21, 22 Tables 2-4) .
Association of high-sensitivity cardiac troponin with incident HF
The pooled hazard ratio for incident HF comparing individuals in the top third versus those in the bottom third of hs-cTn concentration was 2.09 (95% confidence interval:
1.76-2.48, p<0.0001, Figure 2 ). There was evidence of significant heterogeneity with an Figure   3) , but the Egger's test was non-significant (p=0.126).
Association of high-sensitivity cardiac troponin with heart failure subtypes
Two studies reported associations between hs-cTn and heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF) separately. In the PREVEND study, the hazard ratio for those with hs-cTnT in the top versus bottom third was greater for HFrEF 
(1.30-2.68) for HFpEF (36) . No studies reported data regarding heart failure with midrange ejection fraction.
Association of changes in hs-cTn and incident heart failure
Two studies reported the association between changes in hs-cTn over time and incident heart failure. In the Cardiovascular Health Study, in those with a detectable hs-cTnT at baseline, the hazard ratio associated with a >50% increase 2-3 years later was 1.61 (1.32-
1.97) after adjusting for conventional CVD risk factors. In the Atherosclerosis Risk in
Communities Study, the corresponding hazard ratio for a >50% change in hs-cTnT at six years was 1.64 (1.39-1.95) (37) . In those with undetectable hs-cTnT (<5ng/L) at baseline, a detectable value (>5ng/L) at six years was associated with a hazard ratio of
(1.62-2.37) (37).
Incremental discrimination with addition of hs-cardiac troponin
Eight studies reported improvements in the c-index upon assessment of hs-cTn in with cardiac magnetic resonance imaging (21) . In the PEACE study involving patients with stable coronary heart disease, the prevalence of left ventricular ejection fraction between 40-50% was 14.4% in the whole cohort, increasing from 11.4% to 18.4% in the lowest to highest quartile of hs-cTnT (31) . It should however be noted that the association of hs-cTn and incident HF was observed even after exclusion of individuals with left ventricular hypertrophy in the Cardiovascular Health Study (36) .
Natriuretic peptides are the best-studied biomarkers in HF and strong predictors of prognosis in patients with established HF (43) . A recent individual participant data metaanalysis of the association between natriuretic peptide levels and incident HF in the general population reported a risk ratio for individuals the top third versus the bottom third of 3.45 (2.66-4.46) (10) . The magnitude of this association for natriuretic peptide is greater than that observed in our meta-analysis for hs-cTn, however those studies had not adjusted for hs-cTn. While individuals with hs-cTn tend to have higher natriuretic peptide levels (21, 25, 31) , the magnitude of the Spearman correlation co-efficient was modest at 0.36 in the Cardiovascular Health Study (25) . In studies that adjusted for natriuretic peptide in our analysis, the pooled hazard ratio was 2.08 (1.64-2.65), only a slight attenuation of the association without adjustment for natriuretic peptides of 2.39
(1.99-2.87). This suggests that hs-cTn has a strong association with incident HF independent of natriuretic peptide levels. A literature based meta-analysis of 29 studies examining the association between hs-cTn and coronary heart disease and stroke reported risk ratios for the top versus bottom third of 1.59 (95% CI 1.38-1.83) for CHD and 1.35 (95% CI 1.23-1.48) for stroke (4) . Thus the association between hs-cTn and HF is stronger than that for either CHD or stroke, a similar trend to that observed for NTproBNP (10) . With regards to improvement in risk discrimination, the C-index change with additional assessment of hs-cTn was lower than that previously observed for natriuretic peptides (0.01-0.03 vs 0.038) (10) .
It has to be noted that the studies included in our meta-analysis relied on a single measurement of hs-cTn, whereas repeat measurements are likely to be more informative.
In the Cardiovascular Health Study, in individuals with an elevated baseline hs-cTn, those with a further increase at follow-up had a higher HF risk compared with those with no change or a decrease in hs-cTn (25) . This observation is in line with similar data from the ARIC study (37) , suggesting that serial measurements of biomarkers may provide additional information over a single measurement. After developing a biomarker score based on concentrations of five biomarkers, including hs-cTn, investigators from the Framingham Heart Study observed a greater than 6-fold increase in the risk of HF in those with a score in the top quintile versus the bottom quintile (34) . This score also improved discrimination and reclassification in terms of HF risk. Serial testing of biomarkers including hs-cTn and the use of multiple biomarkers simultaneously appears to hold promise, but is inevitably more resource intensive and costly.
Strengths and limitations
This systematic review has pooled data from sixteen studies reporting data from 67,063 participants with 4,165 HF events, giving significant statistical power. This study adds to the existing literature in this field by providing an overview of all the available evidence regarding the association between hs-cTn and heart failure, with particular strengths including the thorough and comprehensive search strategy, transformation of study specific hazard ratios to a common scale to allow comparison and the high methodological quality of the included studies. There are however a number of limitations that merit discussion. There was significant heterogeneity observed in our analyses. No single factor was clearly demonstrated to account for a large proportion of this heterogeneity in meta-regression analyses and it is likely to be multifactorial. The assumption of a normally distributed exposure variable and a linear association with the outcome of interest may have been violated in some studies where individuals were categorized based on hs-cTn levels. A non-linear relationship could lead to an inflated hazard ratio after transformation, however there was no significant interaction between estimates from studies who modeled hs-cTn as a continuous or categorical variable.
Finally, incomplete reporting of confidence intervals for C-index values prevented quantitative synthesis of this data and this element is descriptive only.
Given the potential for both clinical and methodological sources of heterogeneity in the included studies, collating individual-patient-level data from all of these studies would be valuable. This would allow standardization of outcome definitions and covariate adjustment. It would also allow for analysis of associations and assessment for effect modification in important subgroups and standardized assessment of the effect of adding hs-cTn to HF risk prediction models in terms of discrimination and calibration.
Summary
Serum hs-cTn is associated with the risk of incidence HF. The association equally applied to the general population and high-risk populations, and was independent of conventional CVD risk factors and natriuretic peptide levels. Preliminary data showing discrimination improvements in HF risk with hs-cTn assessment suggest it may be a promising biomarker for measurement as part of primary prevention of HF.
Clinical perspective
People with higher levels of circulating cardiac troponin are at higher risk of developing new onset heart failure, after accounting for conventional risk factors and natriuretic peptide levels. Measurement of high sensitivity cardiac troponin improves the discrimination of heart failure risk. High sensitivity cardiac troponin may be useful in identifying individuals at high risk of heart failure to target preventive interventions.
Translational outlook
An individual-participant-data meta-analysis would help clarify the added value of high sensitivity cardiac troponin in the prediction of new onset heart failure, beyond conventional risk factors. Search results and study selection process Forest plot for primary analysis of maximally adjusted hazard ratios for the association between hs-cTn and incident heart failure. Hazard ratios for association between hs-cTn and incident heart failure by the degree of Meta-regression by categorical study level characteristics **Manner in which hazard ratios were reported in original paper. * P-value calculated using meta-regression. Abbreviations -RCT=randomized controlled trial. Change in C-index with addition of hs-cTn by study 
Heterogeneity
